{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:03:28Z","timestamp":1788314608672,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Methicillin-susceptible\n<jats:italic>Staphylococcus aureus<\/jats:italic> (MSSA) is the most common causative microorganism of pyogenic vertebral osteomyelitis (PVO). Although oral antimicrobial therapy with first-generation cephalosporins can treat MSSA infection, data on PVO are scarce. This study evaluated the treatment efficacy of cephalexin as oral antibiotic therapy for MSSA-induced PVO.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective study included adult patients treated with oral cephalexin as the completing treatment for PVO with MSSA bacteremia from 2012 to 2020. Treatment effectiveness of cephalexin was evaluated by comparing improvement (5-point scale; score\u2009\u2265\u20094\/5 indicates treatment success) in symptoms and laboratory and imaging results between intravenous antimicrobial and oral cephalexin treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 15 participants (8 [53%] women; median [interquartile range, IQR], age 75 [67.5\u201380.5] years; Charlson Comorbidity Index 2 [0\u20134]), 10 (67%) had lumbar spine lesions, 12 (80%) had spinal abscesses, and 4 (27%) had remote abscesses; no patients had concomitant endocarditis. In 11 patients with normal renal function, cephalexin 1,500\u20132,000\u00a0mg\/day was administered. Five patients (33%) underwent surgery. Median (IQR; range) duration (days) of intravenous antibiotics, cephalexin, and total treatment was 36 (32\u201361; 21\u201386), 29 (19\u201382; 8\u2013251), and 86 (59\u2013125; 37\u2013337), respectively. Cephalexin had an 87% treatment success rate without recurrence during a median follow-up of 119 (IQR, 48.5\u2013350) days.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In patients with MSSA bacteremia and PVO, antibiotic treatment completion with cephalexin is a reasonable option, even in cases with spinal abscess, if at least 3\u00a0weeks of effective intravenous antimicrobial therapy is provided.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-023-08266-0","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T10:02:19Z","timestamp":1683540139000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effectiveness of oral cephalexin in antibiotic-course completion for methicillin-susceptible Staphylococcus aureus-induced bacteremic vertebral osteomyelitis"],"prefix":"10.1186","volume":"23","author":[{"given":"Nobumasa","family":"Okumura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayoko","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Mezaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Ohmagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,8]]},"reference":[{"issue":"6","key":"8266_CR1","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1093\/cid\/civ482","volume":"61","author":"EF Berbari","year":"2015","unstructured":"Berbari EF, Kanj SS, Kowalski TJ, Darouiche RO, Widmer AF, Schmitt SK, et al. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults. Clin Infect Dis. 2015;61(6):e26-46.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"8266_CR2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1056\/NEJMoa1710926","volume":"380","author":"HK Li","year":"2019","unstructured":"Li HK, Rombach I, Zambellas R, Walker AS, McNally MA, Atkins BL, et al. Oral versus Intravenous Antibiotics for Bone and Joint Infection. N Engl J Med. 2019;380(5):425\u201336.","journal-title":"N Engl J Med"},{"issue":"5","key":"8266_CR3","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"9971","key":"8266_CR4","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(14)61233-2","volume":"385","author":"L Bernard","year":"2015","unstructured":"Bernard L, Dinh A, Ghout I, Simo D, Zeller V, Issartel B, et al. Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial. Lancet. 2015;385(9971):875\u201382.","journal-title":"Lancet"},{"issue":"3","key":"8266_CR5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3947\/ic.2019.51.3.284","volume":"51","author":"WS Oh","year":"2019","unstructured":"Oh WS, Moon C, Chung JW, Choo EJ, Kwak YG, Kim SH, et al. Antibiotic Treatment of Vertebral Osteomyelitis caused by Methicillin-Susceptible Staphylococcus aureus: A Focus on the Use of Oral beta-lactams. Infect Chemother. 2019;51(3):284\u201394.","journal-title":"Infect Chemother"},{"issue":"8","key":"8266_CR6","doi-asserted-by":"publisher","first-page":"ofac366","DOI":"10.1093\/ofid\/ofac366","volume":"9","author":"L Marconi","year":"2022","unstructured":"Marconi L, Tedeschi S, Zamparini E, Terzi S, Rossi N, Boriani L, et al. Oral Versus Standard Antimicrobial Treatment for Pyogenic Native Vertebral Osteomyelitis: A Single-Center, Retrospective, Propensity Score-Balanced Analysis. Open Forum Infect Dis. 2022;9(8):ofac366.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"8266_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jhin.2006.04.015","volume":"64","author":"ME Falagas","year":"2006","unstructured":"Falagas ME, Kopterides P. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect. 2006;64(1):7\u201315.","journal-title":"J Hosp Infect"},{"key":"8266_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k678","volume":"360","author":"B Pasternak","year":"2018","unstructured":"Pasternak B, Inghammar M, Svanstr\u00f6m H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ. 2018;360: k678.","journal-title":"BMJ"},{"issue":"3","key":"8266_CR9","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/j.1476-5381.1969.tb08513.x","volume":"37","author":"PE Gower","year":"1969","unstructured":"Gower PE, Dash CH. Cephalexin: human studies of absorption and excretion of a new cephalosporin antibiotic. Br J Pharmacol. 1969;37(3):738\u201347.","journal-title":"Br J Pharmacol"},{"key":"8266_CR10","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ijid.2019.02.005","volume":"81","author":"AK Thabit","year":"2019","unstructured":"Thabit AK, Fatani DF, Bamakhrama MS, Barnawi OA, Basudan LO, Alhejaili SF. Antibiotic penetration into bone and joints: An updated review. Int J Infect Dis. 2019;81:128\u201336.","journal-title":"Int J Infect Dis"},{"issue":"4","key":"8266_CR11","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1128\/AAC.41.4.739","volume":"41","author":"KJ Tack","year":"1997","unstructured":"Tack KJ, Keyserling CH, McCarty J, Hedrick JA. Study of use of cefdinir versus cephalexin for treatment of skin infections in pediatric patients. The Cefdinir Pediatric Skin Infection Study Group. Antimicrob Agents Chemother. 1997;41(4):739\u201342.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"8266_CR12","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1097\/INF.0b013e3182a222a6","volume":"32","author":"J Autmizguine","year":"2013","unstructured":"Autmizguine J, Watt KM, Theoret Y, Kassir N, Laferriere C, Parent S, et al. Pharmacokinetics and pharmacodynamics of oral cephalexin in children with osteoarticular infections. Pediatr Infect Dis J. 2013;32(12):1340\u20134.","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"8266_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jinf.2014.02.009","volume":"69","author":"KH Park","year":"2014","unstructured":"Park KH, Cho OH, Jung M, Suk KS, Lee JH, Park JS, et al. Clinical characteristics and outcomes of hematogenous vertebral osteomyelitis caused by gram-negative bacteria. J Infect. 2014;69(1):42\u201350.","journal-title":"J Infect"},{"issue":"4","key":"8266_CR14","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1128\/AAC.28.4.467","volume":"28","author":"P Van der Auwera","year":"1985","unstructured":"Van der Auwera P, Klastersky J, Thys JP, Meunier-Carpentier F, Legrand JC. Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections. Antimicrob Agents Chemother. 1985;28(4):467\u201372.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"8266_CR15","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/cid\/ciw098","volume":"62","author":"KH Park","year":"2016","unstructured":"Park KH, Cho OH, Lee JH, Park JS, Ryu KN, Park SY, et al. Optimal Duration of Antibiotic Therapy in Patients With Hematogenous Vertebral Osteomyelitis at Low Risk and High Risk of Recurrence. Clin Infect Dis. 2016;62(10):1262\u20139.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"8266_CR16","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jinf.2008.04.012","volume":"57","author":"DJ Livorsi","year":"2008","unstructured":"Livorsi DJ, Daver NG, Atmar RL, Shelburne SA, White AC Jr, Musher DM. Outcomes of treatment for hematogenous Staphylococcus aureus vertebral osteomyelitis in the MRSA ERA. J Infect. 2008;57(2):128\u201331.","journal-title":"J Infect"},{"key":"8266_CR17","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/1471-2334-14-226","volume":"14","author":"B Babouee Flury","year":"2014","unstructured":"Babouee Flury B, Elzi L, Kolbe M, Frei R, Weisser M, Sch\u00e4ren S, et al. Is switching to an oral antibiotic regimen safe after 2 weeks of intravenous treatment for primary bacterial vertebral osteomyelitis? BMC Infect Dis. 2014;14:226.","journal-title":"BMC Infect Dis"},{"key":"8266_CR18","doi-asserted-by":"crossref","unstructured":"Gupta A, Kowalski TJ, Osmon DR, Enzler M, Steckelberg JM, Huddleston PM, et al. Long-term outcome of pyogenic vertebral osteomyelitis: a cohort study of 260 patients. Open Forum Infect Dis. 2014;1(3):ofu107.","DOI":"10.1093\/ofid\/ofu107"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08266-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08266-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08266-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T10:03:56Z","timestamp":1683540236000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08266-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,8]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8266"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08266-0","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,8]]},"assertion":[{"value":"13 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of the National Center for Global Health and Medicine prior to the study\u2019s initiation (Approval number: NCGM-S-004301\u201300), and it waived the requirement to obtain patient consent. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"307"}}